Clinical trials: SARS-COV 2
SARS-CoV-2 Acute Respiratory Disease, Covid19
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality.
- Trial name
- STC-19 (NCT04371471)
- Testing
- STC-19 score
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
SARS-CoV 2
Lung Irradiation for COVID-19 Pneumonia
In this research study the investigators want to learn more about the potential benefit of radiation to the lung to improve the health of patients who are hospitalized with Coronavirus-19 (COVID-19) due to infection with a virus…
- Trial name
- NCT04393948
- Testing
- Phase 1, Phase 2
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
COVID - 19
Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus
Patients with COVID-19 which are 60 years old or above or with comorbidities are at risk of deteriorating and developing severe illness.
- Trial name
- COSTA (NCT04355052)
- Testing
- hydroxychloroquine in combination with camostat mesylate, Hydroxychloroquine in combination of Azithromycin
- Where
- 2 sites in Israel
- Volunteers
- 250 people
- Sponsor
- Sheba Medical Center
SARS (Severe Acute Respiratory Syndrome)
Quercetin In The Treatment Of SARS-COV 2
In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties.
- Trial name
- QUERCOV (NCT04853199)
- Testing
- Quercetin
- Where
- 2 sites in Tunisia
- Volunteers
- 200 people
- Sponsor
- Hôpital Universitaire Sahloul
Long COVID-19 Syndrome, COVID 19
Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression…
- Conditions
- Long COVID-19 Syndrome, COVID 19, Noncommunicable Disease, Hypertension
- Trial name
- NCT06871293
- Testing
- Functional and cognitive rehabilitation strategy, Evidence-Based Informational Support
- Where
- Colombia
- Volunteers
- 374 people
- Sponsor
- Fundación Cardioinfantil Instituto de Cardiología
Covid-19, SARS-CoV 2
Baricitinib Compared to Standard Therapy in Patients With COVID-19
There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of…
- Conditions
- Covid-19, SARS-CoV 2, SARS Pneumonia
- Trial name
- BARICIVID-19 (NCT04393051)
- Testing
- Baricitinib Oral Tablet
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
COVID-19, SARS-CoV 2
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19
Randomized, double-blind, parallel, two-arms clinical trial to assess the efficacy and safety of 2 infusions of Wharton-Jelly mesenchymal stromal cells (day 1 and day 3, endovenously at 1E6cells/Kg per dose) in patients with…
- Conditions
- COVID-19, SARS-CoV 2, Adult Respiratory Distress Syndrome
- Trial name
- COVIDMES (NCT04390139)
- Testing
- XCEL-UMC-BETA
- Where
- 5 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Banc de Sang i Teixits
Corona Virus Infection, SARS-CoV 2
Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room
Patients with COVID-19 usually present in the ED and receive their initial medical check-up here. We will try to gather information of comorbidities and other conditions at the time of presentation of COVID-19 patients to the ED.
- Trial name
- ReCovER (NCT04351854)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Cologne
Femoral Neck Fractures, SARS-CoV 2
A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic
In early 2020 the evolving COVID-19 Pandemic provided the world and medical community with a generational challenge. As a novel disease, countries were left with strategic decisions and many went into social lockdown.
- Trial name
- NCT04375501
- Testing
- Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail
- Where
- United Kingdom
- Volunteers
- 442 people
- Sponsor
- Barts & The London NHS Trust
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
Kidney Transplant Infection, SARS-CoV Infection
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)
None of the vaccines approved, or in clinical trials, have so far been tested on transplanted patients. If they produce an immune response to the Spike protein of SARS-CoV-2 it is unknown how long the protective immunity will…
- Trial name
- SCV-KTx-imm (NCT04747522)
- Testing
- SARS-CoV-2 vaccine
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
Covid-19
Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19
Odor and taste disturbances have increased dramatically during this time of the COVID-19 pandemic. Currently, we have very little information on the demographic and clinical characteristics of the affected population, on the…
- Trial name
- STras-Cov-2 (NCT04681157)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
- Trial name
- NCT05677893
- Testing
- MBS-COV
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
SARS CoV 2 Infection, SARS CoV 2 Vaccination
COVID-19 Transmission and Morbidity in Malawi
SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the…
- Trial name
- COVID-TMM (NCT05973084)
- Where
- 2 sites in United States, Malawi
- Volunteers
- 1,500 people
- Sponsor
- Boston University
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Convalescent Plasma, COVID-19
Efficacy and Safety of COVID-19 Convalescent Plasma
Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
- Conditions
- Convalescent Plasma, COVID-19, SARS-CoV 2
- Trial name
- NCT04397523
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- North Macedonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Transfusion Medicine of RNM
COVID
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients
Currently, no effective treatments are available for the COVID-19 pandemic, which is related to more than 70,000 deaths all over the world.
- Trial name
- NCT04346446
- Testing
- Convalescent Plasma Transfusion, Supportive Care, Random Donor Plasma
- Where
- 2 sites in India
- Volunteers
- 29 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
COVID-19, SARS CoV 2 Infection
STREngthening COronavirus Disease 2019 (COVID-19) Surveillance in Africa
The aim of this observational study was to develop, with the intended users, an epidemic surveillance and response system that will be effective, sensitive, coordinated and appropriate.
- Conditions
- COVID-19, SARS CoV 2 Infection, COVID-19 Pandemic
- Trial name
- STREESCO (NCT06170320)
- Where
- Benin
- Volunteers
- 7,000 people
- Sponsor
- Institut de Recherche pour le Developpement
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection), Hospitalized Patients
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd immunity.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection), Hospitalized Patients, Laboratory-confirmed SARS-CoV 2 Infection
- Trial name
- No-SARS (NCT04520880)
- Testing
- Testing procedure for Binding antibodies, Neutralizing antibodies
- Where
- Saudi Arabia
- Volunteers
- 158 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
COVID-19
Seroprevalence of Covid-19 in the Staff of the University Hospitals of Strasbourg
The Grand Est region is one of the most affected regions in France during the first wave of the COVID-19 epidemic. A significant increase in the number of patients hospitalized for SARS-CoV 2 infection at the University Hospitals…
- Trial name
- SeroPrevHUS (NCT05652582)
- Where
- France
- Volunteers
- 5,694 people
- Sponsor
- University Hospital, Strasbourg, France